Alerts will be sent to your verified email
Verify Email
UNICHEMLAB
|
Unichem Lab
|
Sequent Scientific
|
Guj. Themis Biosyn
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
41.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
27.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
7.38 % | 0.0 | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
-2.21 % | 1.28 % | 41.95 % |
|
5yr average Equity Multiplier
|
1.28 | 2.12 | 1.37 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 0.92 | 0.89 |
|
5yr Avg Net Profit Margin
|
-3.85 % | 0.94 % | 34.6 % |
|
Price to Book
|
1.7 | 6.55 | 14.28 |
|
P/E
|
30.25 | 211.01 | 72.76 |
|
5yr Avg Cash Conversion Cycle
|
80.33 Days | 55.84 Days | -31.8 Days |
|
Inventory Days
|
146.44 Days | 76.26 Days | 23.52 Days |
|
Days Receivable
|
128.35 Days | 87.51 Days | 48.29 Days |
|
Days Payable
|
225.53 Days | 117.98 Days | 135.34 Days |
|
5yr Average Interest Coverage Ratio
|
-0.08 | 2.31 | 187.52 |
|
5yr Avg ROCE
|
-0.47 % | 7.29 % | 54.74 % |
|
5yr Avg Operating Profit Margin
|
2.2 % | 8.58 % | 45.69 % |
|
5 yr average Debt to Equity
|
0.09 | 0.5 | 0.05 |
|
5yr CAGR Net Profit
|
3.21 % | n/a | 20.11 % |
|
5yr Average Return on Assets
|
-1.68 % | 0.71 % | 30.29 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
70.22 % | 52.61 % | 70.86 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 3.3 % |
|
Change in Promoter Holding (3 Yrs)
|
19.29 % | -0.41 % | -4.13 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
1.71 % | 9.92 % | 1.14 % |
|
Unichem Lab
|
Sequent Scientific
|
Guj. Themis Biosyn
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|